fig4

Figure 4. Multitargeted therapy for MASH: a superior approach compared with single-target therapy. In the treatment of MASH, the concept that “multitargeted therapy is superior to single-target therapy” has gradually become a consensus in clinical research and practice. The core reason lies in the complexity of MASH pathogenesis, which involves multiple intertwined links and pathways. Single-target drugs struggle to cover the entire chain of disease progression, whereas multitargeted therapeutic strategies can more effectively modulate the core pathological mechanisms, enhance therapeutic efficacy, and overcome the limitations of single intervention approaches. Created in BioRender. Fu R (2025) https://BioRender.com/qoyo58m. MASH: Metabolic dysfunction-associated steatohepatitis.